Salarius Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Salarius Pharmaceuticals, Inc.

6 hours	Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform SLRX GlobeNewswire
Dec-01	Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study SLRX GlobeNewswire
Nov-19	Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol "SLRX" SLRX GlobeNewswire
Nov-13	Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger SLRX GlobeNewswire
Oct-13	Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements SLRX GlobeNewswire
Sep-09	Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement SLRX GlobeNewswire
Aug-14	Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split SLRX GlobeNewswire
Jul-14	Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard SLRX GlobeNewswire
Jul-09	Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies SLRX GlobeNewswire